GlaxoSmithKline plc logo Shares of GlaxoSmithKline plc (NYSE:GSK) have been assigned a consensus rating of “Hold” from the twenty-five ratings firms that are currently covering the company, Market Beat.
GlaxoSmithKline (LSE: GSK) is often pegged as a super-safe income stock due to the rock solid demand for drugs - and its 5.8% dividend yield - but the fact is this business is in transition and at the moment its payout looks perilously uncovered ...
Who is the real competitor to AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK)? In an obvious way they're competing with each other and with the other major blockbuster drug researchers around the world.
GlaxoSmithKline plc LON:GSK NYSE:GSK today announced an agreement with Novartis Pharma AG, a subsidiary of Novartis AG NYSE:NVS, to divest its rights in ofatumumab for auto-immune indications, including multiple sclerosis.